A real-world retrospective analysis comparing the effectiveness of Azvudine and Nirmatrelvir/Ritonavir in COVID-19 patients with diabetes.

Interpreting the mortality trend and key secondary outcomes A notable observation was a numerical trend favoring NMV-r for all-cause mortality reduction (adjusted hazard ratio [aHR] = 0.502).

also in 691 other papers

Contextualizing findings with existing literature and subgroup analysis Our finding that the potential mortality benefit of NMV-r was most pronounced (though still borderline significant) in patients with severe diabetes (HR = 0.37, 95% CI: 0.11–1.00) is hypothesis-generating.

also in 5,455 other papers

In severe diabetes patients (HR = 0.37, 95% CI: 0.11–1.00), although this result did not reach statistical significance.

also in 60,398 other papers